RT Journal Article
SR Electronic
T1 MSPTDfast: An Efficient Photoplethysmography Beat Detection Algorithm
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.18.24310627
DO 10.1101/2024.07.18.24310627
A1 Charlton, Peter H
A1 Mant, Jonathan
A1 Kyriacou, Panicos A
YR 2024
UL http://medrxiv.org/content/early/2024/07/29/2024.07.18.24310627.abstract
AB Beat detection is a key step in the analysis of photo-plethysmogram (PPG) signals. The ‘MSPTD’ algorithm was recently identified as one of the most accurate beat detection algorithms, but its current open-source implementation is substantially more computationally expensive than other leading algorithms such as ‘qppgfast’. The aim of this work was to develop a more efficient, open-source implementation of the ‘MSPTD’ algorithm. Five potential improvements were identified to increase efficiency. Each potential improvement was evaluated in turn, and an optimal algorithm configuration named ‘MSPTDfast’ was developed which incorporated all of the improvements found to reduce algorithm execution time whilst not substantially reducing the accuracy of beat detection. Performance was assessed using data collected from young adults during a lunchbreak in the PPG-DaLiA dataset. The data consisted of wrist PPG signals acquired using an Empatica E4 device, alongside simultaneous ECG signals from which reference heartbeat timings were obtained. ‘MSPTDfast’ was found to be substantially more efficient than ‘MSPTD’ (a reduction in execution time of 72.3%), with minimal difference in beat detection accuracy (F1-score 87.8% vs. 87.7%). In addition, the performance of ‘MSPTDfast’ was much closer to that of the state-of-the-art ‘qppgfast’ algorithm than the ‘MSPTD’ algorithm, with a comparable F1-score (87.4% vs. 87.7%), and an execution time which was only 19.2% longer than that of ‘qppgfast’ (vs. 330.8% longer for ‘MSPTD’). In conclusion, ‘MSPTD-fast’ is an efficient and accurate open-source PPG beat detection algorithm with a substantially faster execution time than ‘MSPTD’. It is available under the permissive MIT licence.Competing Interest StatementP.H.C. has performed consultancy work for Cambridge University Technical Services, has received travel funds from VascAgeNet, and has received honoraria from IOP Publishing and Emory University (the latter not received personally). J.M. has performed consultancy work for BMS/ Pfizer and Omron.Funding StatementThis study is funded by the British Heart Foundation [FS/20/20/34626].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://doi.org/10.24432/C53890I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study used openly available data that were originally located at: https://doi.org/10.24432/C53890 https://doi.org/10.24432/C53890 https://doi.org/10.5281/zenodo.13121283